Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.52 |
| ▸ | CCKBR | P32239 | 6/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037518 | 0.94 | IL23R (0.53) | MC4RCCKBRCCKARIL23RCTSL | |
| SCHEMBL30264577 | 0.93 | MC4R (0.52) | MC4RKISS1RGHSRC5AR1IL23R | |
| SCHEMBL31016486 | 0.92 | CTSL (0.55) | MC4RCCKBRCCKARC5AR1IL23R | |
| SCHEMBL29476447 | 0.91 | MC4R (0.50) | MC4RCCKBRKISS1RCCKARGHSR | |
| SCHEMBL29476484 | 0.91 | MC4R (0.50) | MC4RCCKBRKISS1RCCKARGHSR | |
| SCHEMBL31016482 | 0.89 | CTSL (0.54) | GHSRC5AR1IL23RCTSLCTSS | |
| SCHEMBL30676242 | 0.89 | CTSL (0.53) | MC4RKISS1RGHSRC5AR1IL23R | |
| SCHEMBL29517075 | 0.89 | C5AR1 (0.54) | MC4RGHSRC5AR1IL23R | |
| SCHEMBL31555133 | 0.88 | MC4R (0.52) | MC4RKISS1RGHSRC5AR1 | |
| SCHEMBL29419493 | 0.88 | MC4R (0.52) | MC4RKISS1RGHSRC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | claimed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | claimed |
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | MC4R 2/4885CCKBR 83/4885KISS1R 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.